CTLA4 and triple-negative breast carcinoma: We tested the impact of EHMT2 knockdown in triple-negative breast cancer (TNBC) cells, a cancer type that is not very responsive to adaptive immune checkpoint blockade therapies (anti-PD-1, anti-CTLA4, etc.)(Adams et al, 2019).